Product | Rights Authorized Region** | Indication | Clinical Trial Approval | Clinical Trial for Registration | Marketing Application | Marketed | Major Marketed Regions** | |||
---|---|---|---|---|---|---|---|---|---|---|
CN | US | EU | JP | |||||||
Diazepam Nasal Spray | For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older |
√
2023.6.7 |
√ | |||||||
Tildrakizumab Injection (Biological Agent) |
For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |
√
2023.5.26 |
√ | √ | √ | |||||
Methotrexate Injection | Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids |
√
2023.3.24 |
√ | |||||||
Active rheumatoid arthritis in adult patients |
√
2024.7.30 |
√ | √ | |||||||
Methylthioninium Chloride Enteric-coated Sustained-release Tablets | A diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy |
√
2024.6.11 |
√ | |||||||
Ruxolitinib cream |
|
Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older |
Approved for marketing in Macau
(2024.4.16) |
√ | √ | |||||
Topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable | √ | |||||||||
Desidustat Tablets | For treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients | |||||||||
Cyclosporine Eye Drops 0.09% | Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye) | √ | √ | |||||||
Latanoprost Eye Drops | Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension | √ | ||||||||
Levetiracetam XR Tablet | Adjunctive therapy for the treatment of partial-onset seizures | √ | ||||||||
BCG for Intravesical Instillation (Biological Agent) |
* | Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence | √ | |||||||
PoNS | Chronic balance deficit due to mild-to-moderate traumatic brain injury |
* Taiwan is not included in the rights authorized region of BCG for Intravesical Instillation
** Major Marketed Regions indicate where products are approved. CMS’s rights are stated by
Rights Authorized Region, CMS has NO development, commercialization or other product rights in unauthorized regions.
Please refer to local prescribing information for more information, including full safety information,
on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 30 August 2024
Product | Rights Authorized Region** | Indication | Pre-clinical | Clinical Trial Approval | Phase I | Phase II | Phase III | Marketing Application** |
---|---|---|---|---|---|---|---|---|
SDN – 037 | Eye pain and inflammation after cataract surgery | |||||||
PDP – 716 | Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension | |||||||
CF101 | Psoriasis | |||||||
ACT017 (Biological Agent) |
Acute phase of ischemic stroke | |||||||
Povorcitinib |
|
Non-segmental vitiligo | ||||||
Hidradenitis suppurativa (HS) | ||||||||
CF102 | Hepatocellular carcinoma | |||||||
Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis | ||||||||
XF – 73 | Prevention of post-surgical staphylococcal infections | |||||||
Y-3 for Injection | * | Used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke | ||||||
VEGFA/ANG2 Tetravalent Bispecific Antibody (Biological Agent) |
Intended for ocular fundus neovascular diseases | |||||||
TYK2 Inhibitor (CMS-D001) |
Intended for psoriasis | |||||||
GnRH Receptor Antagonist (CMS-D002) |
Intended for the treatment of moderate to severe pain associated with endometriosis | |||||||
~10 Self-developed Innovative Drugs | Including large molecules, small molecules and siRNA products, etc. |
* Taiwan is not included in the rights authorized region of Y-3 for Injection.
** Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region,
CMS has NO development, commercialization or other product rights in unauthorized regions.
Please refer to local prescribing information for more information, including full safety information,
on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 30 August 2024